Understanding new PCSK9 outcome data: from the LDL-C hypothesis to LDL-c causality.
Topic:
Lipids
Speaker:
Professor J. Chapman (Paris, FR)
Organised by Physicians' Academy for Cardiovascular Education, supported with an educational grant by Sanofi/Regeneron and Amgen
Event:
ESC Congress 2017
Congress Presentation
About the speaker
Professor John Chapman
Pitie Salpetriere APHP University Hospital, Paris (France)
17
presentations
0
follower
4 more presentations in this session
Introduction - PCSK9 inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies.
Speaker: Doctor M. Farnier (Dijon, FR)
PCSK9 inhibition across a wide spectrum of patients: for whom is it efficacious?
Speaker: Doctor G. Hovingh (Amsterdam, NL)
PCSK9 inhibition & CV events: review of recent and upcoming hard endpoint outcome trials.
Speaker: Professor P. Sever (London, GB)
Discussion - PCSK9 inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies.
Speaker: Professor W. Koenig (Munich, DE) Doctor M. Farnier (Dijon, FR)
Access the full session
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies (EBAC Accredited)
Speakers:
Professor J. Chapman, Doctor M. Farnier, Doctor G. Hovingh, Professor P. Sever, Professor W. Koenig...
About the event
ESC 365 is supported by
